GSK Confirms £500M Investment in Manufacturing Across Multiple U.K. Sites
Decision was prompted by news of tax break on profits from U.K.-owned IP.
Pall Puts Down $185 Million for ATMI
Pall agreed to acquire ATMI LifeSciences for $185 million.
Progenitor Cell Therapy Completes First Stage of Production Plant
The firm expects projects to range from process/product development to clinical development, fill/finish operations, and commercial product manufacturing.
SGI and IDT Pool Expertise to Offer Small Synthetic Gene Products
Firms will produce custom synthetic double-stranded nucleic acids up to 5 kb.
Impax and Perrigo Team Up on Topical Generic
Impax Laboratories will collaborate with Perrigo on the development, manufacturing, and commercialization of an extended topical generic drug product with first-to-market potential.
Promega Continues Expanding in China
Promega opened a new facility in Shanghai for its China operations. The new site replaces an existing molecular biology reagent production site.
Patheon Consolidates Production Activities in Puerto Rico
Contract development and manufacturing services firm offers preclinical development through to commercial manufacturing of parenteral, solid, semisolid, and liquid dosage forms.
Torque Unveils Manufacturing Platform for Its “Deep Primed” T-Cell Cancer Therapies
Torque, a developer of T-cell cancer therapeutics produced through its Deep-Priming™ technology platform, says its Slipstream™ process for making Deep-Primed T-Cells is designed to deliver substantially greater efficiency over current cell therapy manufacturing through savings in cost, time, and labor.
Aldevron to Produce CureLab’s DNA Vaccine for Cancer
Aldevron was selected to produce CureLab Oncology’s DNA-based vaccine for cancer treatment.
BioFactura Scores Nearly $2M for Ebola Therapy and VRP Vaccine Production
TEDCO and DoD Grants will fund Biodefense mAb R&D and manufacturing platform for virus-like replicon particle vaccines.
